Abstract
β-Lapachone, a novel anti-neoplastic drug, induces various cancer cells to undergo apoptosis. In a previous report, we showed that β-lapachone-induced apoptosis of HL-60 cells is mediated by oxidative stress. However, in the present study, we found that β-lapachone-induced apoptosis of human prostate cancer (HPC) cells may be independent of oxidative stress. In contrast to the 10-fold β-lapachone-induced increase in H2O2production seen in HL-60 cells, only a 2- to 4-fold increase was observed in HPC cells. N-acetyl-l-cysteine (NAC), a thiol antioxidant, inhibited the apoptosis in DU145 cells after 12 h exposure to β-lapachone. Nonetheless, NAC, along with other antioxidants, failed to exert similar effect in HPC cells subjected to β-lapachone treatment for 24 h. Under this premise, we suggest that the oxidative stress may not play a crucial role in β-lapachone-mediated HPC cell apoptosis. Here we demonstrate that damage to genomic DNA is the trigger for the apoptosis of HPC cells induced by β-lapachone. According to our results, β-lapachone stimulates DNA dependent kinase expression and poly(ADP-ribose) polymerase cleavage in advance of significant morphological changes. β-Lapachone promotes the expression of cyclin-dependent kinase (cdk) inhibitors (p21WAF1 and p27Kip1), induces bak expression, and subsequently stimulates the activation of caspase-7 but not of caspase-3 or caspase-8 during the apoptosis of HPC cells. Taken together, these results suggest that the signaling pathway involving the β-lapachone-induced apoptosis of HPC cell may be by DNA damage, induction of cdk inhibitors (p21 and p27), and then subsequent stimulation of caspase-7 activation.
Footnotes
- Received March 7, 2000.
- Accepted December 18, 2000.
-
Send reprint requests to: Yat-Pang Chau, Ph.D., Institute of Anatomy and Cell Biology, School of Life Science, National Yang-Ming University, 155, 2nd Sec., Li-Nung Street, Shih-Pai, Taipei, Taiwan 112, Republic of China. E-mail: leonchau{at}ym.edu.tw
-
This work was supported by Grants NSC89-2314-B-010-029 from the National Science Council, VTY88-G5–04 from Veterans General Hospital, Tsin-Hua, Yang-Ming Research Program and awarded by Medical Research and Advancement Foundation in Memory of Dr. Chi-Shuen Tsou.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|